RADIATION THERAPY ONCOLOGY GROUP
RTOG 0839
Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
RTOG 0839
Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Protocol Participation Information
- Credentialing
- Credentialing Requirements (Contact RPC at 713-745-8989 with any questions.)
- Facility Questionnaire: Part I and Part III are required for this protocol.
- IGRT Credentialing for RTOG Protocols
- Anonymized Patient Spreadsheet to be submitted with IGRT patient data (updated 5/26/10)
- Submitting IGRT Data to the ITC
- Digital Data Submission
- Digital Data Submission Procedures
- Digital Data Submission Information (DDSI) Form
- ATC Compliant Treatment Planning Systems
Please note: Participants submitting treatment planning data for this protocol using RTOG Data Exchange format should download the ITC MU Reporting Form (Excel spreadsheet), enter the MUs delivered for each beam, and submit the completed spreadsheet along with their digital data submission to the ITC. Please contact Bill Straube (314-362-9762, itc@wustl.edu) for further information. This form is not required for data submission using DICOM.
- Structure Names - Please refer to protocol text for structure naming requirements.
- Protocol Text (http://www.rtog.org)
Back to protocols
